{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:51Z","timestamp":1789587051735,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,10,9]],"date-time":"2010-10-09T00:00:00Z","timestamp":1286582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,10,9]],"date-time":"2010-10-09T00:00:00Z","timestamp":1286582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10637-010-9557-5","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T02:29:31Z","timestamp":1287023371000},"page":"723-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study"],"prefix":"10.1007","volume":"30","author":[{"suffix":"Jr","given":"Robert J.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,9]]},"reference":[{"issue":"4","key":"9557_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"9557_CR2","first-page":"1568","volume-title":"Cancer: principles and practice of oncology","author":"SA Cannistra","year":"2008","unstructured":"Cannistra SA, Gershenson D, Recht A (2008) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT Jr, Lawrence TS, Rosenberg S (eds) Cancer: principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia, pp 1568\u20131594"},{"issue":"26","key":"9557_CR3","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950\u20131955","journal-title":"N Engl J Med"},{"issue":"6","key":"9557_CR4","first-page":"833","volume":"12","author":"P Sabbatini","year":"1998","unstructured":"Sabbatini P, Spriggs D (1998) Salvage therapy for ovarian cancer. Oncology 12(6):833\u2013848","journal-title":"Oncology"},{"key":"9557_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ijc.2910560420","volume":"56","author":"C Stanwell","year":"1994","unstructured":"Stanwell C, Gescher A, Bradshaw TD, Pettit GR (1994) The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer 56:585\u2013592","journal-title":"Int J Cancer"},{"key":"9557_CR6","first-page":"101","volume":"52","author":"RL Hornung","year":"1992","unstructured":"Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101\u2013107","journal-title":"Cancer Res"},{"key":"9557_CR7","first-page":"3242","volume":"49","author":"IL Dale","year":"1989","unstructured":"Dale IL, Bradshaw TD, Gescher A, Pettit GR (1989) Comparison of effects of bryostatins 1 and 2 and 12-O- tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49:3242\u20133245","journal-title":"Cancer Res"},{"key":"9557_CR8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0006-2952(94)90484-7","volume":"47","author":"WD Jarvis","year":"1994","unstructured":"Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S (1994) Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47:839\u2013852","journal-title":"Biochem Pharmacol"},{"key":"9557_CR9","first-page":"3716","volume":"55","author":"C Asiedu","year":"1995","unstructured":"Asiedu C, Biggs J, Lilly M, Kraft AS (1995) Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin- dependent kinase 2. Cancer Res 55:3716\u20133720","journal-title":"Cancer Res"},{"key":"9557_CR10","first-page":"3119","volume":"52","author":"A Basu","year":"1992","unstructured":"Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cis- diamminedichloroplatinum(II) by bryostatin 1. Cancer Res 52:3119\u20133124","journal-title":"Cancer Res"},{"key":"9557_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/ijc.2910420313","volume":"42","author":"J Hofmann","year":"1988","unstructured":"Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Uberall F, Grunicke HH (1988) Enhancement of the antiproliferative effect of cis- diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382\u2013388","journal-title":"Int J Cancer"},{"key":"9557_CR12","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/S0021-9258(19)39638-3","volume":"265","author":"S Isonishi","year":"1990","unstructured":"Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O- tetradecanoylphorbol 13-acetate. J Biol Chem 265:3623\u20133627","journal-title":"J Biol Chem"},{"key":"9557_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"9557_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"9557_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss G (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239\u2013253","journal-title":"Invest New Drugs"},{"key":"9557_CR16","first-page":"881","volume":"55","author":"C Stanwell","year":"1994","unstructured":"Stanwell C (1994) The role of protein kinase C (PKC) modulation in the antiproliferative effects of bistratene A, bryostatin 1 and phorbol esters. Diss Abstr Int [C] 55:881","journal-title":"Diss Abstr Int [C]"},{"key":"9557_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/ijc.2910430129","volume":"43","author":"IL Dale","year":"1989","unstructured":"Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43:158\u2013163","journal-title":"Int J Cancer"},{"key":"9557_CR18","first-page":"682","volume":"51","author":"LM Schuchter","year":"1991","unstructured":"Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51:682\u2013687","journal-title":"Cancer Res"},{"key":"9557_CR19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.1998.16.1.56","volume":"16","author":"ML Varterasian","year":"1998","unstructured":"Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non- Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16:56\u201362","journal-title":"J Clin Oncol"},{"key":"9557_CR20","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1016\/S0021-9258(19)38909-4","volume":"265","author":"A Basu","year":"1990","unstructured":"Basu A, Teicher BA, Lazo JS (1990) Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 265:8451\u20138457","journal-title":"J Biol Chem"},{"key":"9557_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.phrs.2007.04.001","volume":"55","author":"G Martiny-Baron","year":"2007","unstructured":"Martiny-Baron G, Fabbro D (2007) Classical PKC isoforms in cancer. Pharmacol Res 55:477\u2013486","journal-title":"Pharmacol Res"},{"key":"9557_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/j.seminoncol.2006.04.009","volume":"33","author":"M Serova","year":"2006","unstructured":"Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E (2006) Preclinical and clinical development of novel agents that target the protein kinase C Family. Sem Oncol 33:466\u2013478","journal-title":"Sem Oncol"},{"issue":"16","key":"9557_CR23","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2174\/1381612043384376","volume":"10","author":"A-R Hanauske","year":"2004","unstructured":"Hanauske A-R, Sundell K, Lahn M (2004) The role of protein kinases C-alpha (PKC-\u03b1) in cancer and its modulation by the novel PKC-\u03b1-specific inhibitor aprinocarsen. Curr Pharm Des 10(16):1923\u20131936","journal-title":"Curr Pharm Des"},{"key":"9557_CR24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00280-009-0931-y","volume":"64","author":"AC Pavlick","year":"2009","unstructured":"Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F (2009) Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 64:803\u2013810","journal-title":"Cancer Chemother Pharmacol"},{"key":"9557_CR25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/bjc.1995.449","volume":"72","author":"PF Hickman","year":"1995","unstructured":"Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL, Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72:998\u20131003","journal-title":"Br J Cancer"},{"key":"9557_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/bjc.1996.224","volume":"73","author":"CH Thompson","year":"1996","unstructured":"Thompson CH, Macaulay VM, O\u2019Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL, Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73:1161\u20131165","journal-title":"Br J Cancer"},{"issue":"2","key":"9557_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3816\/CLC.1999.n.013","volume":"1","author":"HJ Lenz","year":"1999","unstructured":"Lenz HJ, Raghavan D, Doroshow J, Gandara DR (1999) Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer. Clin Lung Cancer 1(2):151\u2013152","journal-title":"Clin Lung Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9557-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9557-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9557-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9557-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:19:15Z","timestamp":1678558755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9557-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,9]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["9557"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9557-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,9]]},"assertion":[{"value":"21 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}